Cell-mediated drug delivery

Expert Opinion on Drug Delivery

Volumn 8, Issue 4, 2011, Pages 415-433

  Batrakova, Elena V ^a   Gendelman, Howard E ^a,b,c   Kabanov, Alexander V ^a,c,d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

Cell carriers; drug delivery; immunocytes; nanoparticles; targeted drug transport

Indexed keywords

ADENOSINE; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; ATAZANAVIR; BETA INTERFERON; BETAMETHASONE SODIUM PHOSPHATE; BRAIN DERIVED NEUROTROPHIC FACTOR; CATALASE; CHLOROQUINE; CHOLINE ACETYLTRANSFERASE; CILIARY NEUROTROPHIC FACTOR; CISPLATIN; CURCUMIN; CYTOTOXIC AGENT; DOPAMINE; DOXORUBICIN; EFAVIRENZ; FLUOROURACIL; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GOLD NANOPARTICLE; INDINAVIR; IRINOTECAN; NERVE GROWTH FACTOR; ONCOLYTIC ADENOVIRUS; QUANTUM DOT; RITONAVIR; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VASCULOTROPIN;

ALZHEIMER DISEASE; ASCITES TUMOR; BLOOD BRAIN BARRIER; BREAST CANCER; BRONCHUS INJURY; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CELL HOMING; CELL IMMORTALIZATION; CELL INFILTRATION; CELL MEDIATED DRUG DELIVERY; CRYPTOCOCCAL MENINGITIS; DEGENERATIVE DISEASE; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; DRUG TARGETING; DRUG TRANSPORT; EMBRYONIC STEM CELL; EPILEPSY; ERYTHROCYTE; GENETIC ENGINEERING; GLIOMA; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYBRIDOMA CELL CULTURE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; INFLAMMATION; INFLAMMATORY DISEASE; LUNG INJURY; LYMPHOCYTE; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MESENCHYMAL STEM CELL; MONOCYTE; NEURAL STEM CELL; NEUTROPHIL; NONHUMAN; OVARY CANCER; PARKINSON DISEASE; PHAGOCYTOSIS; REVIEW; STEM CELL; STRIATONIGRAL DEGENERATION; T LYMPHOCYTE;

ANIMALS; BLOOD-BRAIN BARRIER; CHEMOTAXIS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; EXOCYTOSIS; HUMANS; NANOSTRUCTURES; PHAGOCYTES; PHARMACEUTICAL PREPARATIONS; STEM CELLS; SURFACE PROPERTIES;

EID: 79952916450     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2011.559457     Document Type: Review

References (111)

1. Fujiwara M, Baldeschwieler JD, Grubbs RH. Receptor-mediated endocytosis of poly(acrylic acid)- conjugated liposomes by macrophages. Biochim Biophys Acta 1996;1278(1):59-67
2. Torchilin VP. Drug targeting. Eur J Pharm Sci 2000;11(Suppl 2):S81-91
3. Mora M, Sagrista ML, Trombetta D, et al. Design and characterization of liposomes containing long-chain N-acylPEs for brain delivery: Penetration of liposomes incorporating GM1 into the rat brain. Pharm Res 2002;19(10):1430-8 (Pubitemid 35266546)
4. Aoki H, Kakinuma K, Morita K, et al. Therapeutic efficacy of targeting chemotherapy using local hyperthermia and thermosensitive liposome: Evaluation of drug distribution in a rat glioma model. Int J Hyperthermia 2004;20(6):595-605 (Pubitemid 39162540)
5. Kabanov AV, Chekhonin VP, Alakhov V, et al. The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles. Micelles as microcontainers for drug targeting. FEBS Lett 1989;258(2):343-5 (Pubitemid 20001084)
6. Kabanov AV, Vinogradov SV, Suzdaltseva YG, et al. Water-soluble block polycations as carriers for oligonucleotide delivery. Bioconjug Chem 1995;6(6):639-43
7. Kabanov A, Alakhov V. Pluronic block copolymers in drug delivery: From micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst 2002;19(1):1-72 (Pubitemid 34521248)
8. Kwon GS. Polymeric micelles for delivery of poorly water-soluble compounds. Crit Rev Ther Drug Carrier Syst 2003;20(5):357-403 (Pubitemid 38129592)
9. Vinogradov S, Batrakova E, Kabanov A. Poly(ethylene glycol)- polyethyleneimine NanoGel (TM) particles: Novel drug delivery systems for antisense oligonucleotides. Colloids Surf B Biointerfaces 1999;16(1-4):291-304 (Pubitemid 29486816)
10. Vinogradov SV, Batrakova EV, Kabanov AV. Nanogels for oligonucleotide delivery to the brain. Bioconjug Chem 2004;15(1):50-60 (Pubitemid 38165980)
11. Gref R, Minamitake Y, Peracchia M, et al. Biodegradable long-circulating polymeric nanospheres. Science 1994;263(5153):1600-3 (Pubitemid 24128361)
12. Hyuk IS, Jeong U, Xia Y. Polymer hollow particles with controllable holes in their surfaces. Nat Mater 2005;4(9):671-5 (Pubitemid 43090730)
13. Calvo P, Gouritin B, Chacun H, et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 2001;18(8):1157-66 (Pubitemid 32900402)
14. Nowacek AS, Miller RL, McMillan J, et al. NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomed 2009;4(8):903-17. This study describes characterization of nanoformulated antiretroviral drugs for HIV-1 infection and its application for human cell-mediated drug delivery.
15. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47(1):3-19 (Pubitemid 32209229)
16. Friedrich I, Reichl S, Muller-Goymann CC. Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS). Int J Pharm 2005;305(1-2):167-75 (Pubitemid 41562227)
17. Harada A, Kataoka K. Chain length recognition: Core-shell supramolecular assembly from oppositely charged block copolymers. Science 1999;283(5398):65-7 (Pubitemid 29044846)
18. Jaturanpinyo M, Harada A, Yuan X, et al. Preparation of bionanoreactor based on core-shell structured polyion complex micelles entrapping trypsin in the core cross-linked with glutaraldehyde. Bioconjug Chem 2004;15(2):344-8 (Pubitemid 38365194)
19. Bull SR, Guler MO, Bras RE, et al. Self-assembled peptide amphiphile nanofibers conjugated to MRI contrast agents. Nano Lett 2005;5(1):1-4 (Pubitemid 40168894)
20. Guler MO, Pokorski JK, Appella DH, et al. Enhanced oligonucleotide binding to self-assembled nanofibers. Bioconjug Chem 2005;16(3):501-3 (Pubitemid 40696040)
21. Juliano R, Stamp D. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem Biophys Res Commun 1975;63:651-8
22. Lee KD, Hong K, Papahadjopoulos D. Recognition of liposomes by cells: In vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. Biochim Biophys Acta 1992;1103(2):185-97
23. Nishikawa K, Arai H, Inoue K. Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages. J Biol Chem 1990;265(9):5226-31
24. Miller CR, Bondurant B, McLean SD, et al. Liposome-cell interactions in vitro: Effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 1998;37(37):12875-83 (Pubitemid 28433520)
25. Ishihara T, Izumo N, Higaki M, et al. Role of zinc in formulation of PLGA/ PLA nanoparticles encapsulating betamethasone phosphate and its release profile. J Control Release 2005;105(1-2):68-76 (Pubitemid 40805476)
26. Tempone AG, Perez D, Rath S, et al. Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: The use of drugs entrapped in liposomes containing phosphatidylserine. J Antimicrob Chemother 2004;54(1):60-8 (Pubitemid 39028968)
27. Krieger M. Molecular flypaper and atherosclerosis: Structure of the macrophage scavenger receptor. Trends Biochem Sci 1992;17(4):141-6
28. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 1999;17:593-623 (Pubitemid 29241135)
29. Zhao Y, Haney MJ, Klyachko NL, et al. Polyelectrolyte complex optimization for macrophage delivery of redox enzyme nanoparticles. Nanomedicine (Lond) 2011;6(1):25-42
30. Harada A, Kataoka K. Pronounced activity of enzymes through the incorporation into the core of polyion complex micelles made from charged block copolymers. J Control Release 2001;72(1-3):85-91 (Pubitemid 32522346)
31. Harada A, Kataoka K. Switching by pulse electric field of the elevated enzymatic reaction in the core of polyion complex micelles. J Am Chem Soc 2003;125(50):15306-7 (Pubitemid 37532170)
32. Knop K, Hoogenboom R, Fischer D, et al. Poly(ethylene glycol) in drug delivery: Pros and cons as well as potential alternatives. Angew Chem Int Ed Engl 2010;49(36):6288-308
33. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clin Pharmacokinet 2003;42(5):419-36 (Pubitemid 36649037)
34. Papaldo P, Fabi A, Ferretti G, et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: Changing the natural history of HER2-positive disease. Ann Oncol 2006;17(4):630-6
35. Gbadamosi JK, Hunter AC, Moghimi SM. PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. FEBS Lett 2002;532(3):338-44 (Pubitemid 35441370)
36. Daleke DL, Hong K, Papahadjopoulos D. Endocytosis of liposomes by macrophages: Binding, acidification and leakage of liposomes monitored by a new fluorescence assay. Biochim Biophys Acta 1990;1024(2):352-66 (Pubitemid 20182822)
37. Jain S, Mishra V, Singh P, et al. RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting. Int J Pharm 2003;261(1-2):43-55 (Pubitemid 36962744)
38. Thiele L, Merkle HP, Walter E. Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. Pharm Res 2003;20(2):221-8 (Pubitemid 36269728)
39. Fahmy TM, Schneck JP, Saltzman WM. A nanoscopic multivalent antigen-presenting carrier for sensitive detection and drug delivery to T cells. Nanomedicine 2007;3(1):75-85 (Pubitemid 46428189)
40. Tabata Y, Ikada Y. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 1988;9(4):356-62
41. Mizushima Y, Hamano T, Yokoyama K. Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion. Ann Rheum Dis 1982;41(3):263-7 (Pubitemid 12087764)
42. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: Relevance to drug delivery. Cell Mol Life Sci 2009;66(17):2873-96
43. Cannon GJ, Swanson JA. The macrophage capacity for phagocytosis. J Cell Sci 1992;101(Pt 4):907-13
44. Champion JA, Katare YK, Mitragotri S. Making polymeric micro- and nanoparticles of complex shapes. Proc Natl Acad Sci USA 2007;104(29):11901-4 (Pubitemid 47185602)
45. Behr J-P. The proton sponge: A trick to enter cells the viruses did not exploit CHIMIA. Int J Chem 1997;51(1):34-6 (Pubitemid 127033737)
46. Cheng H, Kastrup CJ, Ramanathan R, et al. Nanoparticulate cellular patches for cell-mediated tumoritropic delivery. ACS Nano 2010;4(2):625-31
47. Krantz A. Red cell-mediated therapy: Opportunities and challenges. Blood Cells Mol Dis 1997;23(1):58-68 (Pubitemid 27310958)
48. Batrakova EV, Li S, Reynolds AD, et al. A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjug Chem 2007;18(5):1498-506. This paper reported the development and characterization of a cell-mediated delivery system of antioxidant enzyme catalase. Loading, release and protection of enzymatic activity of catalase in bone marrow-derived monocytes are evaluated in an in vitro model of Parkinson's disease. (Pubitemid 47464057)
49. Sollner T, Bennett MK, Whiteheart SW, et al. A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion. Cell 1993;75(3):409-18 (Pubitemid 23335067)
50. Ikehara Y, Niwa T, Biao L, et al. A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res 2006;66(17):8740-8 (Pubitemid 44449191)
51. Perry VH, Bell MD, Brown HC, et al. Inflammation in the nervous system. Curr Opin Neurobiol 1995;5(5):636-41
52. Kuby J. Immunology. Freeman, WH. and Co., New York; 1994
53. Anthony DC, Bolton SJ, Fearn S, et al. Age-related effects of interleukin-1 beta on polymorphonuclear neutrophil-dependent increases in blood-brain barrier permeability in rats. Brain 1997;120(Pt 3):435-44 (Pubitemid 27153636)
54. Anthony DC, Blond D, Dempster R, et al. Chemokine targets in acute brain injury and disease. Prog Brain Res 2001;132:507-24
55. Blamire AM, Anthony DC, Rajagopalan B, et al. Interleukin-1beta-induced changes in blood-brain barrier permeability, apparent diffusion coefficient, and cerebral blood volume in the rat brain: A magnetic resonance study. J Neurosci 2000;20(21):8153-9
56. Persidsky Y, Ghorpade A, Rasmussen J, et al. Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis. Am J Pathol 1999;155(5):1599-611
57. Dou H, Destache CJ, Morehead JR, et al. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 2006;108(8):2827-35
58. Pawlowski NA, Kaplan G, Abraham E, et al. The selective binding and transmigration of monocytes through the junctional complexes of human endothelium. J Exp Med 1988;168(5):1865-82 (Pubitemid 19023268)
59. Lossinsky AS, Shivers RR. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions [review]. Histol Histopathol 2004;19(2):535-64 (Pubitemid 38450634)
60. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410(6829):701-5 (Pubitemid 32290358)
61. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 2001;98(18):10344-9 (Pubitemid 32803022)
62. Hofstetter CP, Schwarz EJ, Hess D, et al. Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. Proc Natl Acad Sci USA 2002;99(4):2199-204 (Pubitemid 34169038)
63. Mahmood A, Lu D, Lu M, et al. Treatment of traumatic brain injury in adult rats with intravenous administration of human bone marrow stromal cells. Neurosurgery 2003;53(3):697-702, discussion-3
64. Martinez-Serrano A, Hantzopoulos PA, Bjorklund A. Ex vivo gene transfer of brain-derived neurotrophic factor to the intact rat forebrain: Neurotrophic effects on cholinergic neurons. Eur J Neurosci 1996;8(4):727-35 (Pubitemid 26114617)
65. Martinez-Serrano A, Bjorklund A. Ex vivo nerve growth factor gene transfer to the basal forebrain in presymptomatic middle-aged rats prevents the development of cholinergic neuron atrophy and cognitive impairment during aging. Proc Natl Acad Sci USA 1998;95(4):1858-63 (Pubitemid 28103484)
66. Muller FJ, Snyder EY, Loring JF. Gene therapy: Can neural stem cells deliver? Nat Rev Neurosci 2006;7(1):75-84 (Pubitemid 41828933)
67. Leek RD, Lewis CE, Whitehouse R, et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996;56(20):4625-9 (Pubitemid 26338061)
68. Lewis JS, Landers RJ, Underwood JC, et al. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol 2000;192(2):150-8
69. Ranney DF, Huffaker HH. Magnetic microspheres for the targeted controlled release of drugs and diagnostic agents. Ann NY Acad Sci 1987;507:104-19
70. Hendriks JJ, Teunissen CE, de Vries HE, et al. Macrophages and neurodegeneration. Brain Res Brain Res Rev 2005;48(2):185-95 (Pubitemid 40585749)
71. Brynskikh AM, Zhao Y, Mosley RL, et al. Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine (Lond) 2010;5(3):379-96. This study supports the feasibility of cell-mediated drug delivery to the brain by examining: The nanozyme loading capacity for cell carriers; the effect of nanozymes on cell viability and function; and the neuroprotective activities of BMM-carried nanozyme against MPTP intoxication in an in vivo model of Parkinson's disease.
72. Low WC, Lewis PR, Bunch ST, et al. Function recovery following neural transplantation of embryonic septal nuclei in adult rats with septohippocampal lesions. Nature 1982;300(5889):260-2 (Pubitemid 13234732)
73. Garcia P, Youssef I, Utvik JK, et al. Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer's disease. J Neurosci 2010;30(22):7516-27
74. Pizzo DP, Coufal NG, Lortie MJ, et al. Regulatable acetylcholineproducing fibroblasts enhance cognitive performance. Mol Ther 2006;13(1):175-82 (Pubitemid 41763496)
75. Blurton-Jones M, Kitazawa M, Martinez-Coria H, et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci USA 2009;106(32):13594-9
76. Zurn AD, Tseng J, Aebischer P. Treatment of Parkinson's disease. Symptomatic cell therapies: Cells as biological minipumps. Eur Neurol 1996;36(6):405-8 (Pubitemid 126753350)
77. Akerud P, Canals JM, Snyder EY, et al. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J Neurosci 2001;21(20):8108-18 (Pubitemid 32952767)
78. Casper D, Engstrom SJ, Mirchandani GR, et al. Enhanced vascularization and survival of neural transplants with ex vivo angiogenic gene transfer. Cell Transplant 2002;11(4):331-49 (Pubitemid 34863219)
79. Yasuhara T, Shingo T, Muraoka K, et al. Neurorescue effects of VEGF on a rat model of Parkinson's disease. Brain Res 2005;1053(1-2):10-8 (Pubitemid 41116785)
80. Biju K, Zhou Q, Li G, et al. Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: A therapeutic strategy for Parkinson's disease. Mol Ther 2010;18(8):1536-44
81. Dou H, Morehead JR, Destache C, et al. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human nomocyte-derived macrophages. Virology 2007;358(1):148-58 (Pubitemid 46048870)
82. Dou H, Grotepas CB, McMillan JM, et al. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol 2009;183(1):661-9
83. Nowacek AS, McMillan J, Miller R, et al. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: Implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol 2010;5(4):592-601
84. Duzgunes N, Pretzer E, Simoes S, et al. Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells. Mol Membr Biol 1999;16(1):111-18 (Pubitemid 29179345)
85. Chokri M, Lopez M, Oleron C, et al. Production of human macrophages with potent antitumor properties (MAK) by culture of monocytes in the presence of GM-CSF and 1,25-dihydroxy vitamin D3. Anticancer Res 1992;12(6B):2257-60 (Pubitemid 23105442)
86. Studeny M, Marini FC, Champlin RE, et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002;62(13):3603-8 (Pubitemid 34728832)
87. Stagg J, Lejeune L, Paquin A, et al. Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy. Hum Gene Ther 2004;15(6):597-608 (Pubitemid 41071207)
88. Nakamura K, Ito Y, Kawano Y, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004;11(14):1155-64 (Pubitemid 39117311)
89. Choi MR, Stanton-Maxey KJ, Stanley JK, et al. A cellular Trojan horse for delivery of therapeutic nanoparticles into tumors. Nano Lett 2007;7(12):3759-65
90. Studeny M, Marini FC, Dembinski JL, et al. Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004;96(21):1593-603 (Pubitemid 39534883)
91. Stoff-Khalili MA, Rivera AA, Mathis JM, et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat 2007;105(2):157-67 (Pubitemid 47366887)
92. Sonabend AM, Ulasov IV, Tyler MA, et al. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 2008;26(3):831-41
93. Menon LG, Kelly K, Yang HW, et al. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 2009;27(9):2320-30
94. Steinfeld U, Pauli C, Kaltz N, et al. T lymphocytes as potential therapeutic drug carrier for cancer treatment. Int J Pharm 2006;311(1-2):229-36
95. Nakamizo A, Marini F, Amano T, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005;65(8):3307-18 (Pubitemid 40524615)
96. Wang GP, Guan YS, Jin XR, et al. Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites. J Gastroenterol Hepatol 2010;25(5):985-90
97. MacDiarmid JA, Mugridge NB, Weiss JC, et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 2007;11(5):431-45 (Pubitemid 46670079)
98. MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol 2009;27(7):643-51
99. Nikaido H. Multidrug efflux pumps of gram-negative bacteria. J Bacteriol 1996;178(20):5853-9 (Pubitemid 26337766)
100. Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 2003;67(4):593-656 (Pubitemid 37549772)
101. Poole K. Outer membranes and efflux: The path to multidrug resistance in Gram-negative bacteria. Curr Pharm Biotechnol 2002;3(2):77-98 (Pubitemid 34520926)
102. Dubrot J, Portero A, Orive G, et al. Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells. Cancer Immunol Immunother 2010;59(11):1621-31
103. Popescu MA, Toms SA. In vivo optical imaging using quantum dots for the management of brain tumors. Expert Rev Mol Diagn 2006;6(6):879-90 (Pubitemid 44904004)
104. Zarabi B, Nan A, Zhuo J, et al. Macrophage targeted N-(2- hydroxypropyl)methacrylamide conjugates for magnetic resonance imaging. Mol Pharm 2006;3(5):550-7 (Pubitemid 44639132)
105. Kumar A, El-Badri N, Glaum M, et al. Initial observations of cell mediated drug delivery to the deep lung. Cell Transplant 5 Nov 2010 [Epub ahead of print]
106. Staedtke V, Brahler M, Muller A, et al. In vitro inhibition of fungal activity by macrophage-mediated sequestration and release of encapsulated amphotericin B nanosupension in red blood cells. Small 2010;6(1):96-103
107. Khan MA, Jabeen R, Nasti TH, et al. Enhanced anticryptococcal activity of chloroquine in phosphatidylserine-containing liposomes in a murine model. J Antimicrob Chemother 2005;55(2):223-8 (Pubitemid 40331149)
108. Boison D. Engineered adenosine-releasing cells for epilepsy therapy: Human mesenchymal stem cells and human embryonic stem cells. Neurotherapeutics 2009;6(2):278-83
109. Boison D. Adenosine augmentation therapies (AATs) for epilepsy: Prospect of cell and gene therapies. Epilepsy Res 2009;85(2-3):131-41
110. Kabanov AV, Batrakova EV. Polymer nanomaterials. In: Gendelman HE, Ikezu T, editors, Neuroimmune pharmacology. Springer, Omaha; 2008. p. 691-707
111. Nowacek A, Gendelman HE. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine 2009;4(5):557-74